BioSpace News Archive

Findings from SURMOUNT-1, the first investigational phase 3 trial evaluating the safety and efficacy of tirzepatide for the treatment of obesity, were announced, representing a new class of medicines being studied for the treatment of obesity.

Updated results from the ELEVATE-TN Phase III trial showed AstraZeneca’s CALQUENCE® maintained a statistically significant progression-free survival benefit versus chlorambucil plus obinutuzumab and a safety and tolerability profile consistent with the known profile for CALQUENCE at a median follow up of approximately five years in combination and as a monotherapy in chronic lymphocytic leukemia.

Biomea Fusion, Inc. presented new data at the American Diabetes Association Scientific Sessions demonstrating BMF-219’s strong, prolonged glycemic control, insulin sensitization, and HbA1c reduction in two preclinical rat models of diabetes.

vTv Therapeutics Inc. announced that the results from the JDRF-supported mechanistic study assessing effects of TTP399 on ketones during acute insulin withdrawal were published in the Diabetes Obesity and Metabolism journal and presented at The American Diabetes Association’s 82nd Scientific Sessions on June 5th.

Findings from an international study show a once-weekly injection of dulaglutide was superior in improving glycemic control in youth with type 2 diabetes compared to placebo.

New data presented at the 82nd Scientific Sessions of the American Diabetes Association® revealed the incidence of severe diabetic ketoacidosis among children with type 1 diabetes was significantly higher during the pandemic compared to pre-pandemic.

A new study reveals that diabetes is a potential risk factor for post-acute sequelae of COVID-19, also known as long COVID-19, a range of post-COVID-19 symptoms such as brain fog, skin conditions, depression, and shortness of breath.

A new study powered by artificial intelligence, Whole Body Digital Twin, reveals the highest reported rate of remission of type 2 diabetes to date.

Agendia, Inc. announced it will share findings in a poster discussion debuting initial data from its ImPrint test, a 53-gene signature in development, at the American Society of Clinical Oncology Annual Meeting 2022.

Two studies provide evidence that social determinants of health account for disparities in health outcomes related to diabetes.